Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04839575 · ClinicalTrials.gov registry record · Phase 2
Study of Latiglutenase in T1D/CD Patients
A Phase 2 study, sponsored by Entero Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT04839575 is a Phase 2 study that was terminated before completion, run by Entero Therapeutics. The registered enrollment target is 13 participants.
The verdict
NCT04839575, a Phase 2 study, was terminated before completion, sponsored by Entero Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
This is a phase 2, single-center prospective, double-blind, placebo-controlled, crossover study in Type 1 diabetes and celiac disease subjects attempting a GFD for at least one year prior to screening.
Interventions
- DRUG Placebo
- DRUG Latiglutenase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2021-04-06 |
| Est. Completion | 2022-12-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04839575
The ClinicalTrials.gov registry entry for NCT04839575 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Entero Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04839575 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04839575 about?
NCT04839575 is a clinical study titled "Study of Latiglutenase in T1D/CD Patients". This is a phase 2, single-center prospective, double-blind, placebo-controlled, crossover study in Type 1 diabetes and celiac disease subjects attempting a GFD for at least one year prior to screening.
What is the current status of trial NCT04839575?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2021-04-06. Estimated completion is 2022-12-19.
What interventions are being tested in trial NCT04839575?
The interventions under investigation include: Placebo (DRUG), Latiglutenase (DRUG).
Who is sponsoring clinical trial NCT04839575?
This trial is sponsored by Entero Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.